
CAS 500577-51-5
:Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
5 produits concernés.
Cyclo(L-arginylglycyl-L-a-aspartyl-D-phenylalanyl-L-lysyl),mono(trifluoroacetate)
CAS :Formule :C29H42F3N9O9Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :717.69392-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid Trifluoroacetate
CAS :2-((2S,5R,8S,11S)-8-(4-Aminobutyl)-5-Benzyl-11-(3-Guanidinopropyl)-3,6,9,12,15-Pentaoxo-1,4,7,10,13-Pentaazacyclopentadecan-2-Yl)Acetic Acid TrifluoroacetateDegré de pureté :98%Masse moléculaire :717.69g/molCyclo(-RGDfK) TFA
CAS :Cyclo(-RGDfK) is a selective αvβ3 integrin inhibitor(IC50 : 0.94 nM).Formule :C29H42F3N9O9Degré de pureté :98.99% - 99.54%Couleur et forme :SolidMasse moléculaire :717.69Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate
CAS :Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate is a cyclic peptide that has been shown to be an effective chemotherapeutic agent against bladder cancer. Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate binds to the integrin receptor on the tumor cell surface and blocks the formation of new blood vessels, which may lead to tumor growth inhibition. The hypoxic tumor environment is characterized by low oxygen levels, which causes the mitochondria in cells to produce more hydrogen peroxide. Cyclo(-Arg-Gly-Asp-D-Phe-Lys) trifluoroacetate has been shown to decrease the production of hydrogen peroxide in hypoxic tumors. This drug also inhibits angiogenesis and cellular proliferation. Cyclo(-Arg-Gly-Asp) trifluoroacetate hasFormule :C27H41N9O7•C2HF3O2Degré de pureté :Min. 98 Area-%Couleur et forme :White Off-White PowderMasse moléculaire :717.7 g/mol



